Pfizer says early data indicates COVID-19 vaccine is effective
Drug manufacturer Pfizer has released interim results of a large-scale clinical trial in over 43,000 participants of its COVID-19 vaccine candidate that show a 90% effectiveness at preventing the disease. While the announcement brought praise from government and medical officials, it is important to understand that data points around the protection rate could change once full results are brought forward. Canada has pre-ordered 20 million doses of Pfizer’s vaccine candidate, assuming it receives independent regulatory approval. Distribution of the vaccine will be a complex process for a number of reasons, among them that Pfizer’s candidate needs to be shipped and centrally stored at minus 70 degrees Celsius; at the site of administration, it can be kept for up to five days at fridge temperatures.
Published: November 9, 2020
CBC NewsRead Article